Novel fusion protein for treating autoimmune diseases
AssigneeCurogen Technology Co., Ltd.
InventorsHyun-Soo KIM, Hee Kyung MIN, Boseul SONG, Jiyeon OH, Jehoon YANG, Minsok CHO, In Seong HWANG, Nuri LIM, Eun Ku KIM
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel fusion protein for the treatment of autoimmune diseases that significantly reduces the expression of pro-inflammatory cytokines without side effects and demonstrates excellent therapeutic efficacy against various autoimmune diseases.
Claims49
An IL-17RA/RC variant hybrid protein having a sequence homology of at least 90% to the amino acid sequence of SEQ ID NO:
- 69 and comprising amino acid substitutions selected from the group consisting of:
- i) Q267R,
- ii) T24D, N88D, D122G, and Q267R,
- iii) T24D, F59V, N88D, D122G, and Q267R,
- iv) L9P, T24D, F59V, N88D, D122G, and Q267R, and
- v) L9P, T24D, F59V, N88D, D122G, A156P, and Q267R.
A TNFR2 ECD variant protein having a sequence homology of at least 90% to the amino acid sequence of SEQ ID NO:
- 77 and comprising amino acid substitutions selected from the group consisting of:
- i) S33A,
- ii) S33A and S36P,
- iii) S33A, S36P, and R119S,
- iv) S33A, S36P, R119S, and N164S,
- v) S33A, S36P, R119S, N164S, and E210G,
- vi) S33A, S36P, R119S, N164S, E210G, and F219I,
- vii) S33A, S36P, G75S, R119S, N164S, E210G, F219I,
- viii) G75S, and
- ix) S33A, S36P, G75S, R119S, and N164S.
A triple fusion protein comprising:
- an IL-17RA/RC variant hybrid protein linked to the N-terminus of an antibody Fc domain, and an extra cellular domain (ECD) of tumor necrosis factor 2 (TNFR2) linked to the C-terminus the antibody Fc domain;
- or
- the ECD of TRFR2 is linked to the N-terminus of the antibody Fc domain and the IL-17RA/RC variant hybrid protein is linked to the C-terminus of the antibody Fc domain.
Dependencies are inferred from the claim text.